Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

INDP Indaptus Therapeutics

Watchlist
2.310
-0.030-1.28%
Trading Session 09/26 09:30 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.310
Open
2.310
Turnover
1.33K
Low
2.310
Pre Close
2.340
Volume
572
Market Cap
19.08M
P/E(TTM)
Loss
52wk High
8.174
Shares
8.26M
P/E(Static)
Loss
52wk Low
1.890
Float Cap
10.61M
Bid/Ask %
0.00%
Historical High
1600.000
Shs Float
4.59M
Volume Ratio
4.83
Historical Low
1.890
Dividend TTM
--
Div Yield TTM
--
P/B
0.63
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.01%
Amplitude
0.00%
Avg Price
2.318
Lot Size
1
Float Cap
10.61M
Bid/Ask %
0.00%
Historical High
1600.000
Shs Float
4.59M
Volume Ratio
4.83
Historical Low
1.890
Dividend TTM
--
P/B
0.63
Dividend LFY
--
Turnover Ratio
0.01%
Amplitude
0.00%
Avg Price
2.318
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top